

Douglas J Macneil

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12078529/publications.pdf>

Version: 2024-02-01

49
papers

5,394
citations

172207

29
h-index

197535

49
g-index

51
all docs

51
docs citations

51
times ranked

5656
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of Spirocyclic Aldosterone Synthase Inhibitors as Potential Treatments for Resistant Hypertension. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 128-132.	1.3	12
2	The Role of Melanin-Concentrating Hormone and Its Receptors in Energy Homeostasis. <i>Frontiers in Endocrinology</i> , 2013, 4, 49.	1.5	65
3	Discovery of pyrimidine carboxamides as potent and selective CCK1 receptor agonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 2911-2915.	1.0	12
4	Liver and Adipose Expression Associated SNPs Are Enriched for Association to Type 2 Diabetes. <i>PLoS Genetics</i> , 2010, 6, e1000932.	1.5	161
5	Melanin-concentrating hormone 1-receptor antagonist suppresses body weight gain correlated with high receptor occupancy levels in diet-induced obesity mice. <i>European Journal of Pharmacology</i> , 2009, 624, 77-83.	1.7	19
6	Validation of candidate causal genes for obesity that affect shared metabolic pathways and networks. <i>Nature Genetics</i> , 2009, 41, 415-423.	9.4	257
7	Identification of novel and orally active spiroindoline NPY Y5 receptor antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 1564-1568.	1.0	19
8	MCH receptor peptide agonists and antagonists. <i>Peptides</i> , 2009, 30, 2008-2013.	1.2	10
9	2-Substituted piperazine-derived imidazole carboxamides as potent and selective CCK1R agonists for the treatment of obesity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 4833-4837.	1.0	27
10	Deficiency in Cytosolic Malic Enzyme Does Not Increase Acetaminophen-Induced Hepato-Toxicity. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2008, 103, 36-42.	1.2	9
11	Variations in DNA elucidate molecular networks that cause disease. <i>Nature</i> , 2008, 452, 429-435.	13.7	840
12	Effects of a Novel Y5 Antagonist in Obese Mice: Combination With Food Restriction or Sibutramine. <i>Obesity</i> , 2008, 16, 1510-1515.	1.5	23
13	Antagonism of central melanin-concentrating hormone 1 receptor alleviates steatohepatitis in mice. <i>Journal of Endocrinology</i> , 2008, 198, 309-315.	1.2	13
14	NPY Y1 and Y5 Receptor Selective Antagonists as Anti-Obesity Drugs. <i>Current Topics in Medicinal Chemistry</i> , 2007, 7, 1721-1733.	1.0	48
15	A Pair-Feeding Study Reveals That a Y5 Antagonist Causes Weight Loss in Diet-Induced Obese Mice by Modulating Food Intake and Energy Expenditure. <i>Molecular Pharmacology</i> , 2007, 71, 602-608.	1.0	40
16	Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. <i>Cell Metabolism</i> , 2006, 4, 275-282.	7.2	174
17	Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 13866-13871.	3.3	96
18	2-Aminoquinoline melanin-concentrating hormone (MCH)1R antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 5270-5274.	1.0	32

#	ARTICLE	IF	CITATIONS
19	4-Aminoquinoline melanin-concentrating hormone 1-receptor (MCH1R) antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 5275-5279.	1.0	14
20	A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain and associated parameters in diet-induced obese mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 7154-7158.	3.3	72
21	Neuropeptide Y receptors as targets of obesity treatment. <i>Expert Opinion on Therapeutic Patents</i> , 2006, 16, 1701-1712.	2.4	11
22	NPY and energy homeostasis: an opportunity for novel anti-obesity therapies. , 2006, , 143-156.		2
23	Increased Melanin Concentrating Hormone Receptor Type 1 in the Human Hypothalamic Infundibular Nucleus in Cachexia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 2412-2419.	1.8	15
24	Antiobesity Effect of a Melanin-Concentrating Hormone 1 Receptor Antagonist in Diet-Induced Obese Mice. <i>Endocrinology</i> , 2005, 146, 3080-3086.	1.4	73
25	Chronic administration of nalmefene leads to increased food intake and body weight gain in mice. <i>European Journal of Pharmacology</i> , 2004, 495, 63-66.	1.7	10
26	Synergistic effects of cannabinoid inverse agonist AM251 and opioid antagonist nalmefene on food intake in mice. <i>Brain Research</i> , 2004, 999, 227-230.	1.1	61
27	Expression, refolding, and purification of recombinant human phosphodiesterase 3B: definition of the N-terminus of the catalytic core. <i>Protein Expression and Purification</i> , 2004, 35, 225-236.	0.6	8
28	The role of tryptophan 1072 in human PDE3B inhibitor binding. <i>Biochemical and Biophysical Research Communications</i> , 2003, 307, 1045-1050.	1.0	6
29	Characterization of Neuropeptide Y (NPY) Y5 Receptor-Mediated Obesity in Mice: Chronic Intracerebroventricular Infusion of d-Trp34NPY. <i>Endocrinology</i> , 2003, 144, 1793-1801.	1.4	57
30	Neither Agouti-Related Protein nor Neuropeptide Y Is Critically Required for the Regulation of Energy Homeostasis in Mice. <i>Molecular and Cellular Biology</i> , 2002, 22, 5027-5035.	1.1	383
31	Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive, and hyperphagic and have altered metabolism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 3240-3245.	3.3	529
32	Synthesis and Biological Evaluation in Vitro of a Selective, High Potency Peptide Agonist of Human Melanin-concentrating Hormone Action at Human Melanin-concentrating Hormone Receptor 1. <i>Journal of Biological Chemistry</i> , 2002, 277, 13821-13826.	1.6	23
33	Melanin-Concentrating Hormone Receptor Subtypes 1 and 2: Species-Specific Gene Expression. <i>Genomics</i> , 2002, 79, 785-792.	1.3	258
34	Synthesis and Biological Evaluation in Vitro of Selective, High Affinity Peptide Antagonists of Human Melanin-Concentrating Hormone Action at Human Melanin-Concentrating Hormone Receptor 1. <i>Biochemistry</i> , 2002, 41, 6383-6390.	1.2	47
35	Novel Sesquiterpenoids from the Fermentation of <i>Xylariapericaria</i> Are Selective Ligands for the NPY Y5 Receptor. <i>Journal of Organic Chemistry</i> , 2002, 67, 5001-5004.	1.7	56
36	Short Segment of Human Melanin-Concentrating Hormone That Is Sufficient for Full Activation of Human Melanin-Concentrating Hormone Receptors 1 and 2. <i>Biochemistry</i> , 2001, 40, 9379-9386.	1.2	29

#	ARTICLE	IF	CITATIONS
37	Insights about the biosynthesis of the avermectin deoxysugar L-oleandrose through heterologous expression of <i>Streptomyces avermitilis</i> deoxysugar genes in <i>Streptomyces lividans</i> . <i>Chemistry and Biology</i> , 2001, 8, 681-700.	6.2	49
38	Role of the Y1 Receptor in the Regulation of Neuropeptide Y-Mediated Feeding: Comparison of Wild-Type, Y1 Receptor-Deficient, and Y5 Receptor-Deficient Mice. <i>Endocrinology</i> , 2000, 141, 1011-1016.	1.4	218
39	L-152,804: Orally Active and Selective Neuropeptide Y Y5 Receptor Antagonist. <i>Biochemical and Biophysical Research Communications</i> , 2000, 272, 169-173.	1.0	135
40	Production of the antitumor drug epirubicin (4-epidoxorubicin) and its precursor by a genetically engineered strain of <i>Streptomyces peucetius</i> . <i>Nature Biotechnology</i> , 1998, 16, 69-74.	9.4	147
41	NPY-induced feeding involves the action of a Y1-like receptor in rodents. <i>Regulatory Peptides</i> , 1998, 75-76, 409-415.	1.9	55
42	Cloning and Expression of a Novel Neuropeptide Y Receptor. <i>Journal of Biological Chemistry</i> , 1996, 271, 16435-16438.	1.6	249
43	Correlation of the Avermectin Polyketide Synthase Genes to the Avermectin Structure: Implications for Designing Novel Avermectins. <i>Annals of the New York Academy of Sciences</i> , 1994, 721, 123-132.	1.8	25
44	Analysis of <i>Streptomyces avermitilis</i> genes required for avermectin biosynthesis utilizing a novel integration vector. <i>Gene</i> , 1992, 111, 61-68.	1.0	684
45	Complex organization of the <i>Streptomyces avermitilis</i> genes encoding the avermectin polyketide synthase. <i>Gene</i> , 1992, 115, 119-125.	1.0	184
46	Vectors for generating nested deletions and facilitating subcloning G + C-rich DNA between <i>Escherichia coli</i> and <i>Streptomyces</i> sp.. <i>Gene</i> , 1992, 119, 149-150.	1.0	10
47	Transformation of <i>Streptomyces avermitilis</i> by plasmid DNA. <i>Journal of Industrial Microbiology</i> , 1987, 2, 209-218.	0.9	66
48	Introduction of plasmid DNA into <i>Streptomyces lividans</i> by electroporation. <i>FEMS Microbiology Letters</i> , 1987, 42, 239-244.	0.7	46
49	A flexible boiling procedure for isolating plasmid DNA from gram-positive microorganisms. <i>Journal of Microbiological Methods</i> , 1986, 5, 115-123.	0.7	11